Source: Lancet infectious diseases. Unidade: FM
Subjects: ANTICORPOS, IMUNOGENICIDADE DA VACINA, MÉTODO DUPLO-CEGO, VÍRUS DA DENGUE
ABNT
KALLÁS, Esper Georges et al. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial. Lancet infectious diseases, v. 20, n. 7, p. 839-850, 2020Tradução . . Disponível em: https://doi.org/10.1016/S1473-3099(20)30023-2. Acesso em: 23 ago. 2024.APA
Kallás, E. G., Precioso, A. R., Palacios, R., Thome, B., Braga, P. E., Vanni, T., et al. (2020). Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial. Lancet infectious diseases, 20( 7), 839-850. doi:10.1016/S1473-3099(20)30023-2NLM
Kallás EG, Precioso AR, Palacios R, Thome B, Braga PE, Vanni T, Campos LMA, Ferrari L, Mondini G, Kalil Filho JE. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial [Internet]. Lancet infectious diseases. 2020 ; 20( 7): 839-850.[citado 2024 ago. 23 ] Available from: https://doi.org/10.1016/S1473-3099(20)30023-2Vancouver
Kallás EG, Precioso AR, Palacios R, Thome B, Braga PE, Vanni T, Campos LMA, Ferrari L, Mondini G, Kalil Filho JE. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial [Internet]. Lancet infectious diseases. 2020 ; 20( 7): 839-850.[citado 2024 ago. 23 ] Available from: https://doi.org/10.1016/S1473-3099(20)30023-2